Scarica l'app Stockscreener
317.74
0.11%
0.36
Dopo l'orario di chiusura:
318.34
0.60
+0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$317.38
Aprire:
$317.3
Volume 24 ore:
2.19M
Relative Volume:
0.83
Capitalizzazione di mercato:
$171.10B
Reddito:
$35.89B
Utile/perdita netta:
$7.01B
Rapporto P/E:
24.56
EPS:
12.9352
Flusso di cassa netto:
$11.54B
1 W Prestazione:
-3.68%
1M Prestazione:
-5.51%
6M Prestazione:
+6.88%
1 anno Prestazione:
+15.94%
Intervallo 1D:
$315.19
$319.46
Intervallo di 1 settimana:
$312.38
$329.67
Portata 52W:
$253.30
$346.38
Amgen Inc Stock (AMGN) Company Profile
Nome
Amgen Inc
Settore
Industria
Telefono
(805)447-1000
Indirizzo
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Confronta AMGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
317.74 | 170.90B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-05 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-11-24 | Ripresa | Truist | Hold |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-03 | Ripresa | Raymond James | Mkt Perform |
| 2025-05-20 | Ripresa | Guggenheim | Neutral |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-14 | Downgrade | Truist | Buy → Hold |
| 2024-09-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Aggiornamento | Truist | Hold → Buy |
| 2023-10-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-17 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Ripresa | BofA Securities | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-04-24 | Reiterato | Oppenheimer | Outperform |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Reiterato | Truist | Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Underperform |
| 2022-10-31 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-09 | Reiterato | Barclays | Equal Weight |
| 2022-02-09 | Reiterato | Jefferies | Buy |
| 2022-02-09 | Reiterato | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Reiterato | Oppenheimer | Outperform |
| 2022-02-09 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-09-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Iniziato | Daiwa Securities | Buy |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Aggiornamento | Truist | Hold → Buy |
| 2020-10-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Downgrade | Truist | Buy → Hold |
| 2020-10-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Ripresa | Guggenheim | Neutral |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-03-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-17 | Ripresa | Morgan Stanley | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-19 | Downgrade | Mizuho | Buy → Neutral |
| 2019-05-23 | Aggiornamento | Citigroup | Neutral → Buy |
Mostra tutto
Amgen Inc Borsa (AMGN) Ultime notizie
Assessing Amgen (AMGN)’s Valuation After FDA Approval of Uplizna for Generalized Myasthenia Gravis - simplywall.st
Treasurer of the State of North Carolina Boosts Stake in Amgen Inc. $AMGN - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Has $23.15 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Bellevue Group AG Sells 56,827 Shares of Amgen Inc. $AMGN - MarketBeat
Banque Transatlantique SA Sells 141,712 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen’s Uplizna Approved For Its Largest And Most Competitive Indication Yet - Citeline News & Insights
FDA Grants Orphan Status to Amgen's (AMGN) Blinatumomab for Leuk - GuruFocus
Amgen (AMGN) Receives Maintained Rating, Price Target Lowered to - GuruFocus
FDA Approves Amgen’s UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease - Yahoo Finance
FDA Approves Amgen's Drug For Rare Muscle Disorder - Benzinga
Amgen (AMGN) Gains FDA Nod for Expanded Use of Uplizna in Myasth - GuruFocus
Morgan Stanley Adjusts Amgen Price Target to $304 From $329, Maintains Equalweight Rating - marketscreener.com
Amgen wins FDA nod for Uplizna in myasthenia gravis (AMGN) - Seeking Alpha
Quantinno Capital Management LP Purchases 19,014 Shares of Amgen Inc. $AMGN - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Lowers Holdings in Amgen Inc. $AMGN - MarketBeat
Peapack Gladstone Financial Corp Has $30.82 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Sei Investments Co. - MarketBeat
Amgen Says FDA Approves Uplizna For Autoimmune Disorder Treatment - marketscreener.com
FDA approves Amgen’s UPLIZNA for generalized myasthenia gravis - Investing.com
FDA Approves Amgen's UPLIZNA for New Myasthenia Gravis Treatment - GuruFocus
FDA approves Amgen’s UPLIZNA for generalized myasthenia gravis By Investing.com - Investing.com Australia
Amgen (NASDAQ:AMGN) gets FDA OK for Uplizna as first CD19 B-cell therapy for gMG - Stock Titan
The Manufacturers Life Insurance Company Reduces Position in Amgen Inc. $AMGN - MarketBeat
NewEdge Advisors LLC Grows Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer - GlobeNewswire Inc.
Wells Fargo Maintains Amgen (AMGN) Equal-Weight Recommendation - Nasdaq
Amgen Inc. (NASDAQ:AMGN) Announces Quarterly Dividend of $2.52 - MarketBeat
Amgen describes new GTPase KRAS mutant inhibitors - BioWorld MedTech
Amgen: Improving Balance Sheet Is Bringing The Stock Close To Being A "Buy" (NASDAQ:AMGN) - Seeking Alpha
Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Intact Investment Management Inc. Sells 10,800 Shares of Amgen Inc. $AMGN - MarketBeat
Ossiam Sells 13,818 Shares of Amgen Inc. $AMGN - MarketBeat
Wells Fargo Adjusts Price Target on Amgen to $325 From $300, Maintains Equalweight Rating - marketscreener.com
HSBC Adjusts Price Target on Amgen to $425 From $381, Maintains Buy Rating - marketscreener.com
Amgen (AMGN) to Participate in Upcoming Virtual Meeting - GuruFocus
Amgen Announces Dividend for the First Quarter of 2026, Payable on March 6, 2026 - marketscreener.com
Amgen Raises Quarterly Dividend to $2.52 a Share From $2.38, Payable March 6 to Shareholders of Record as of Feb. 13 - marketscreener.com
Amgen declares $2.52 per share dividend for first quarter 2026 By Investing.com - Investing.com UK
AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND - PR Newswire
Key facts: Amgen invests $900M in Ohio; hosts Clinical Research Forum in UAE - TradingView
State Street Corp Increases Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by SVB Wealth LLC - MarketBeat
Who Owns Amgen? Top Shareholders and Recent Insider Trades - TIKR.com
Fayez Sarofim & Co Acquires 18,213 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Daiwa Securities Group Inc. - MarketBeat
Bank of Nova Scotia Has $29.83 Million Stake in Amgen Inc. $AMGN - MarketBeat
Axa S.A. Purchases 103,665 Shares of Amgen Inc. $AMGN - MarketBeat
Rep. David Taylor Sells Amgen Inc. (NASDAQ:AMGN) Stock - MarketBeat
Amgen Inc. $AMGN Shares Bought by L2 Asset Management LLC - MarketBeat
Gabelli Funds LLC Sells 3,150 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Position Boosted by Federated Hermes Inc. - MarketBeat
Amgen Inc Azioni (AMGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amgen Inc Azioni (AMGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Sale |
337.26 |
3,139 |
1,058,667 |
7,225 |
2.28%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):